Eli Lilly stock price slips after-hours as hospitals push back on new 340B data rule
Eli Lilly shares slipped 0.1% to $1,062.75 in after-hours trading Monday after the American Hospital Association urged U.S. regulators to block Lilly’s expanded 340B claims-data policy before a Feb. 1 deadline. The move comes as investors await Lilly’s Feb. 4 earnings and an FDA decision on its oral obesity drug.